The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study

被引：105

作者：

Nakamura, Tomoki ^{[1
]}

Matsumine, Akihiko ^{[1
]}

Kawai, Akira ^{[2
]}

Araki, Nobuhito ^{[3
]}

Goto, Takahiro ^{[4
]}

Yonemoto, Tsukasa ^{[5
]}

Sugiura, Hideshi ^{[6
,7
]}

Nishida, Yoshihiro ^{[8
]}

Hiraga, Hiroaki ^{[9
]}

Honoki, Kanya ^{[10
]}

Yasuda, Taketoshi ^{[11
]}

Boku, Shogen ^{[12
]}

Sudo, Akihiro ^{[1
]}

Ueda, Takafumi ^{[13
]}

机构：

[1] Mie Univ, Dept Orthoped Surg, Grad Sch Med, Tsu, Mie 514, Japan

[2] Natl Canc Ctr, Div Orthoped Surg, 1-1 Tsukiji 5 chome, Tokyo, Japan

[3] Osaka Gen Med Ctr, Dept Orthoped Surg, Osaka, Japan

[4] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Orthoped Surg & Musculoskeletal Oncol, Tokyo, Japan

[5] Chiba Canc Ctr, Div Orthoped Surg, 666-2 Nitonacho, Chiba 2608717, Japan

[6] Aichi Canc Ctr, Dept Orthoped Surg, Nagoya, Aichi 464, Japan

[7] Nagoya Univ, Grad Sch Med, Dept Phys Therapy, Nagoya, Aichi 4648601, Japan

[8] Nagoya Univ, Grad Sch Med, Dept Orthoped Surg, Nagoya, Aichi 4648601, Japan

[9] Hokkaido Canc Ctr, Dept Orthoped Surg, Sapporo, Hokkaido, Japan

[10] Nara Med Univ, Dept Orthoped Surg, Nara, Japan

[11] Toyama Univ, Dept Orthoped Surg, Toyama 930, Japan

[12] Hyogo Canc Ctr, Dept Med Oncol, Akashi, Hyogo, Japan

[13] Osaka Natl Hosp, Dept Orthoped Surg, Osaka, Japan

来源：

CANCER | 2016年 / 122卷 / 09期

关键词：

efficacy; pazopanib; progression-free survival; soft tissue sarcoma; toxicity; EUROPEAN ORGANIZATION; ANGIOGENESIS INHIBITOR; PHASE-II; EORTC; EFFICACY;

D O I：

10.1002/cncr.29961

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUNDBecause the efficacy and safety of pazopanib in Japanese patients with soft tissue sarcoma (STS) had not been evaluated previously in a large-scale cohort, the authors investigated the efficacy and safety of pazopanib in 156 Japanese patients with relapsed STS. This was a retrospective study based on the collection of real-life, postmarketing surveillance data. METHODSPatients received pazopanib with the objective of treating local recurrence (n = 20), metastasis (n = 104), and both (n = 32). The patient median age was 53.8 years. The primary objective of this study was to clarify the efficacy of pazopanib for patients with STS. RESULTSThe median treatment duration was 28.7 weeks, and the average dose intensity of pazopanib was 609 mg. Adverse events occurred in 127 patients (81.4%). In addition to the main common toxicities, such as hypertension and liver disorder, pneumothorax (n = 11) and thrombocytopenia (n = 16) also were observed. The median progression-free survival for all patients was 15.4 weeks. The median progression-free survival for patients with leiomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, and liposarcoma was 18.6 weeks, 16.4 weeks, 15.3 weeks, and 8 weeks, respectively. The median survival for all patients was 11.2 months. The median survival for patients with leiomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, and liposarcoma was 20.1 months, 10.6 months, 9.5 months, and 7.3 months, respectively. CONCLUSIONSThere were apparent differences in the efficacy of pazopanib treatment among histologic types of STS. Pazopanib treatment is a new treatment option; however, adverse events like pneumothorax and thrombocytopenia, which did not occur frequently in the PALETTE study (pazopanib for metastatic soft-tissue sarcoma), should be taken into consideration. Cancer 2016;122:1408-16. (c) 2016 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. Clinical outcomes of 156 Japanese patients with relapsed soft tissue sarcoma receive pazopanib treatment are investigated. There are apparent differences in the efficacy of pazopanib treatment among histologic types of soft tissue sarcoma.

引用

页码：1408 / 1416

页数：9